ArticleMedizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V2026
Clinical utility of polygenic risk scores in cardiovascular disorders.
Article in Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polygenic risk scores: en route to clinical practice.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sudden and often fatal onset of many cardiovascular disease (CVD) calls for improved risk prediction and personalized preventive strategies. Polygenic risk score (PRS) captures inherited susceptibility and may add precision to guideline-recommended clinical risk score. Given the spectrum of CVD, the utility of PRS varies from being a clinically meaningful diagnostic tool to a scientific instrument that brings light into the complex aetiologies. This review summarizes the current understanding of PRS in CVD. We discuss methodological strategies for its construction and outline clinical scenarios for PRS across major CVDs, including coronary artery disease, aortic aneurysms, cardiomyopathies, atrial fibrillation in the context of heart failure, and hypertension, highlighting their potential to enhance risk stratification beyond traditional factors. Finally, we outline current knowledge gaps that limit the clinical implementation of PRS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.